AN0025 + Pembrolizumab
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC), Cervical Cancer
Trial Timeline
Aug 20, 2020 → Jan 30, 2025
NCT ID
NCT04432857About AN0025 + Pembrolizumab
AN0025 + Pembrolizumab is a phase 1 stage product being developed by Merck for Triple-negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04432857. Target conditions include Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04432857 | Phase 1 | Active |
Competing Products
20 competing products in Triple-negative Breast Cancer